Evaluation of a program of pharmaceutical counseling for French patients on oral anticoagulant therapy
Background Oral anticoagulants are widely used for treatment and prevention of thromboembolic diseases. We set up a pharmaceutical counseling program for both direct oral anticoagulant and vitamin K antagonist drugs in our hospital in 2015. Objective Evaluate patient satisfaction and the evolution of their knowledge throughout the pharmaceutical counseling program on anticoagulants and identify knowledge variability factors. Setting Cardiology Inpatient Unit from the University Antoine Béclère Hospital, France. Methods Evaluation was based on data collection of patients surveyed between 2015 and 2018. Inpatients in the cardiology department on oral anticoagulants were eligible. The learning process was designed to enhance patient knowledge and understanding based on 10 cognitive or self-management skills, relating to the optimization of oral anticoagulant therapy management. It consisted in 2 face-to-face interviews during hospitalization and 2 additional phone interviews one and six months after discharge. The median patient score was evaluated at each step of the process as well as the mean score for each item from the global population. A sub-analysis was run on the less well-acquired skills in order to identify risk factors for limited knowledge. The association between those factors and the level of knowledge (score ≥ 7 or < 7) was assessed using Chi square test followed by multivariate analysis. Main outcome measure Patient knowledge of anticoagulation therapy depending on specific factors. Results Of the 880 patients eligible for pharmaceutical counseling, 319 entered the process and 102 completed it. Median knowledge scores were 8/10 and 9/10 after the first and the final interviews respectively with a significant improvement (p = 0.0003). The least well-acquired items at each step were surveillance and under-dosing management. The sub-analysis showed the use of vitamin K antagonist to be linked to an enhanced understanding related to treatment surveillance (p = 0.029). Patients suffering from atrial fibrillation were found to have a worse understanding of under-dosing management (p = 0.013). Finally, patients evaluated the process as helpful and suitable for their conditions. Conclusion Pharmaceutical counseling is appropriate for patients, improving and maintaining knowledge of oral anticoagulants. Our evaluation highlights the need to focus on patient-specific profiles to reach a satisfactory level of knowledge.
KeywordsDirect oral anticoagulants DOACs France Patient education Program evaluation Therapy related knowledge Vitamin-K-antagonists
We thank S. Ghouti-Baxter for the English review.
The set-up of the pharmaceutical counseling process was partially funded by a Pulsaction grant supported by Boehringer Ingelheim.
Conflicts of interest
C. Kowal and A. Rieutord reports non-financial support from Pfizer. M-C Chaumais reports non-financial support from Bayer and grants from Boehringer Ingelheim. The other authors report no conflicts of interest.
- 2.2005 - Les événements indésirables graves liés aux soins .pdf [Internet]. [cited 2019 Jul 22]. Available from: https://drees.solidarites-sante.gouv.fr/IMG/pdf/er398-3.pdf.
- 8.Falamić S, Lucijanić M, Hadžiabdić MO, Marušić S, Bačić Vrca V. Pharmacist’s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. Int J Clin Pharm. 2018;Google Scholar
- 11.Amara W, Larsen TB, Sciaraffia E, Hernández Madrid A, Chen J, Estner H, et al. Patients’ attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace. 2016;18:151–5.CrossRefGoogle Scholar
- 13.Keita I, Aubin-Auger I, Lalanne C, Aubert J-P, Chassany O, Duracinsky M, et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence. 2017;11:1625–34.CrossRefGoogle Scholar
- 14.Weernink MGM, Vaanholt MCW, Groothuis-Oudshoorn CGM, von Birgelen C, IJzerman MJ, van Til JA. Patients’ priorities for oral anticoagulation therapy in non-valvular atrial fibrillation: a multi-criteria decision analysis. Am J Cardiovasc Drugs. 2018;18:493–502.Google Scholar
- 17.Décret n° 2017–884 du 9 mai 2017 modifiant certaines dispositions réglementaires relatives aux recherches impliquant la personne humaine. 2017–884 mai, 2017.Google Scholar
- 19.Barbier E, Chaumais M-C, Launay-Vacher G, Rieutord A, Haddad R. Formation de l’équipe pharmaceutique aux consultations antivitamines K (AVK): une expérience de blended-learning à l’hôpital. Journal de Pharmacie Clinique. 2014;33:125–32.Google Scholar
- 20.entretien-pharmaceutique-avk_assurance-maladie.pdf [Internet]. [cited 2018 Dec 7]. Available from: https://www.ameli.fr/sites/default/files/Documents/5393/document/entretien-pharmaceutique-avk_assurance-maladie.pdf.
- 21.Antonio Hernandez Madrid, Tatjana S. Potpara, Nikolaos Dagres, Jian Chen, Torben B. Larsen, Heidi Estner, et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 2015;18:463–467.Google Scholar
- 29.Raparelli V, Proietti M, Cangemi R, Lip GYH, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117:209–18.Google Scholar